Skip to main content

Advertisement

SpringerLink
Log in

Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease

  • Alcohol (M Farrell and E Stockings, Section Editors)
  • Published:
Current Addiction Reports Aims and scope Submit manuscript

Abstract

Purpose

Alcohol consumption is a leading cause of morbidity and mortality in our society and alcohol-related liver disease is a major contributor to this. Abstinence is the most important treatment goal for patients with alcohol-related liver disease and appropriate pharmacotherapy can help to achieve this.

Recent findings

There are a number of established and emerging pharmacotherapies for the treatment of alcohol use disorder that can be used in patients with liver disease although few have been studied extensively in this population. There are conflicting data on the effectiveness of these therapies and alcohol pharmacotherapy is an evolving field where more research is needed. The only effective treatment for alcoholic liver disease is abstinence.

Summary

High-quality comparative studies of pharmacotherapies and further inclusion of patients with comorbidity are needed. While current pharmacotherapies are of modest effect, many can be safely used in patients with alcoholic liver disease which is a major cause of morbidity and mortality where the only effective treatment is abstinence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Hancock DB, Markunas CA, Bierut LJ, Johnson EO. Human genetics of addiction: new insights and future directions. Curr Psychiatry Rep. 2018;20:8.

    Article  PubMed  Google Scholar 

  2. Viken RJ, Kaprio J, Koskenvuo M, Rose RJ. Longitudinal analyses of the determinants of drinking and of drinking to intoxication in adolescent twins. Behav Genet. 1999;29:455–61.

    Article  PubMed  CAS  Google Scholar 

  3. Walker J, Bountress KE, Calhoun CD, Metzger IW, Adams Z, Amstadter A, et al. Impulsivity and comorbid PTSD-binge drinking. J Dual Diagn. 2018:1–20.

  4. Sher KJ, Grekin ER, Williams NA. The development of alcohol use disorders. Annu Rev Clin Psychol. 2005;1:493–523.

    Article  PubMed  Google Scholar 

  5. Corral M, Holguin SR, Cadaveira F. Neuropsychological characteristics of young children from high-density alcoholism families: a three-year follow-up. J Stud Alcohol. 2003;64:195–9.

    Article  PubMed  Google Scholar 

  6. Tabakoff B, Hoffman PL. Alcohol addiction: an enigma among us. Neuron. 1996;16:909–12.

    Article  PubMed  CAS  Google Scholar 

  7. Gorky J, Schwaber J. The role of the gut-brain axis in alcohol use disorders. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;65:234–41.

    Article  CAS  Google Scholar 

  8. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530.e1.

    Article  PubMed  Google Scholar 

  9. Becker U, Deis A, Sørensen TI, Grønbaek M, Borch-Johnsen K, Müller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025–9. https://doi.org/10.1002/hep.510230513.

    Article  PubMed  CAS  Google Scholar 

  10. Stickel F, Hampe J. Genetic determinants of alcoholic liver disease. Gut. 2012;61(1):150–9. https://doi.org/10.1136/gutjnl-2011-301239.

    Article  PubMed  CAS  Google Scholar 

  11. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002;35(3):635–8. https://doi.org/10.1053/jhep.2002.31782.

    Article  PubMed  Google Scholar 

  12. Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis. 2011;31(2):128–46. https://doi.org/10.1055/s-0031-1276643.

    Article  PubMed  CAS  Google Scholar 

  13. Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C, Colell A. Mitochondrial glutathione: importance and transport. Semin Liver Dis. 1998;18(4):389–401.

    Article  PubMed  CAS  Google Scholar 

  14. Ambade A, Mandrekar P. Oxidative stress and inflammation: essential partners in alcoholic liver disease. Int J Hepatol. 2012;2012:853175. https://doi.org/10.1155/2012/853175.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Cao QBR. The role of T lymphocytes in the pathogenesis of ALD. Comprehensive handbook of alcohol-related pathology. London: Elsevier; 2005.

    Google Scholar 

  16. Hill DB, Deaciuc IV, Nanji AA, McClain CJ. Mechanisms of hepatic injury in alcoholic liver disease. Clin Liver Dis. 1998;3:703–21.

    Article  Google Scholar 

  17. Thurman RGII. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Phys. 1998;275(4 Pt 1):G605–11.

    CAS  Google Scholar 

  18. Parés A, Caballería J, Bruguera M, Torres M, Rodés J. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol. 1986;2(1):33–42.

    Article  PubMed  Google Scholar 

  19. Palmentieri B, de SI, La MV, Masarone M, Vecchione R, Bruno S, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis. 2006;38:485–9.

    Article  PubMed  CAS  Google Scholar 

  20. Yu CH, Xu CF, Ye H, Li L, Li YM. Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials. World J Gastroenterol. 2010;16(19):2435–9.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Mathurin P, Lucey MR. Management of alcoholic hepatitis. J Hepatol. 2012;56(Suppl 1):S39–45. https://doi.org/10.1016/S0168-8278(12)60005-1.

    Article  PubMed  CAS  Google Scholar 

  22. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94:1018–22.

    Article  PubMed  CAS  Google Scholar 

  23. Day CP. Treatment of alcoholic liver disease. Liver Transpl. 2007;13(11 Suppl 2):S69–75. https://doi.org/10.1002/lt.21336.

    Article  PubMed  Google Scholar 

  24. • Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011. Validated test to predict liver cirrhosis using only blood testing without imaging or invasive procedures, very high utility in alcohol use disorder population.

  25. Nahon P, Kettaneh A, Tengher-Barna I, Ziol M, de LV, Douvin C, et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol. 2008;49:1062–8.

    Article  PubMed  Google Scholar 

  26. W.R K. OPTN/SRTR Annual Data Report 2014. In: Lake J.R. SJM, Skeans M.A, Schladt D.P, Edwards E.B, Harper A.M, Wainright J.L, Snyder J.J, Israni A.K, Kasiske B.L, editor.: American Journal of Transplantation; 2016. p. 69–98.

  27. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013;59(1):160–8. https://doi.org/10.1016/j.jhep.2013.03.007.

    Article  PubMed  Google Scholar 

  28. Burra P, Senzolo M, Adam R, Delvart V, Karam V, Germani G, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant. 2010;10(1):138–48. https://doi.org/10.1111/j.1600-6143.2009.02869.x.

    Article  PubMed  CAS  Google Scholar 

  29. Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology. 2004;39(3):826–34. https://doi.org/10.1002/hep.20127.

    Article  PubMed  Google Scholar 

  30. Grattagliano I, Ubaldi E, Bonfrate L, Portincasa P. Management of liver cirrhosis between primary care and specialists. World J Gastroenterol. 2011;17(18):2273–82. https://doi.org/10.3748/wjg.v17.i18.2273.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Tang-Barton P, Vas W, Weissman J, Salimi Z, Patel R, Morris L. Focal fatty liver lesions in alcoholic liver disease: a broadened spectrum of CT appearances. Gastrointest Radiol. 1985;10:133–7.

    Article  PubMed  CAS  Google Scholar 

  32. Alexander JF, Lischner MW, Galambos JT. Natural history of alcoholic hepatitis. II. The long-term prognosis. Am J Gastroenterol 1971.

  33. Alvarez MA, Cirera I, Sola R, Bargallo A, Morillas RM, Planas R. Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients. J Clin Gastroenterol. 2011;45:906–11.

    Article  PubMed  Google Scholar 

  34. Orrego H, Blake JE, Israel Y. Relationship between gamma-glutamyl transpeptidase and mean urinary alcohol levels in alcoholics while drinking and after alcohol withdrawal. Alcohol Clin Exp Res. 1985;9(1):10–3.

    Article  PubMed  CAS  Google Scholar 

  35. Mao YM, Zeng MD, Li YM, Wang BY, Shang J, Shi RH, et al. Capsule metadoxine in the treatment of alcoholic liver disease: a randomized, double-blind, placebo-controlled, multicenter study. Zhonghua Gan Zang Bing Za Zhi. 2009;17(3):213–6.

    PubMed  CAS  Google Scholar 

  36. Caballería J, Parés A, Brú C, Mercader J, García Plaza A, Caballería L, et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol. 1998;28(1):54–60.

    Article  PubMed  Google Scholar 

  37. Fede G, Germani G, Gluud C, Gurusamy KS, Burroughs AK. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev. 2011;6:CD002800. https://doi.org/10.1002/14651858.CD002800.pub3.

    Article  Google Scholar 

  38. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev. 2005;2:CD002148. https://doi.org/10.1002/14651858.CD002148.pub2.

    Article  Google Scholar 

  39. Rambaldi A, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev. 2006;4:CD003045. https://doi.org/10.1002/14651858.CD003045.pub2.

    Article  Google Scholar 

  40. Ishii H, Kurose I, Kato S. Pathogenesis of alcoholic liver disease with particular emphasis on oxidative stress. J Gastroenterol Hepatol. 1997;12(9–10):S272–82.

    Article  PubMed  CAS  Google Scholar 

  41. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res. 2003;27(11):1765–72. https://doi.org/10.1097/01.alc.0000093743.03049.80.

    Article  PubMed  CAS  Google Scholar 

  42. Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975;55:347–59.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Leggio L, Lee MR. Treatment of alcohol use disorder in patients with alcoholic liver disease. Am J Med. 2017;130:124–34.

    Article  PubMed  Google Scholar 

  44. Nishimoto A, Usery J, Winton JC, Twilla J. High-dose parenteral thiamine in treatment of Wernicke’s encephalopathy: case series and review of the literature. In Vivo. 2017;31:121–4.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Wilson EC, Stanley G, Mirza Z. The long-term cost to the UK NHS and social services of different durations of IV thiamine (vitamin B1) for chronic alcohol misusers with symptoms of Wernicke’s encephalopathy presenting at the emergency department. Appl Health Econ Health Policy. 2016;14:205–15.

    Article  PubMed  Google Scholar 

  46. Hutcheon DA. Malnutrition-induced Wernicke’s encephalopathy following a water-only fasting diet. Nutr Clin Pract. 2015;30:92–9.

    Article  PubMed  Google Scholar 

  47. Hack JB, Hoffman RS. Thiamine before glucose to prevent Wernicke encephalopathy: examining the conventional wisdom. JAMA. 1998;279:583–4.

    Article  PubMed  CAS  Google Scholar 

  48. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55:vi1–vi12.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Zhao P, Zhao Y, Wei Z, Chen J, Yan L. Wernicke encephalopathy in a patient with liver failure: clinical case report. Medicine (Baltimore) 2016.

  50. • Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2018. Large recent sytematic review and meta-analysis demonstrating paucity of evidence of efficacy for currently used alcohol pharmacotherapies. Suggests topiramate may have superior efficacy but more significant side effects compared to other available pharmacotherapies.

  51. Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014;77:315–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010.

  53. Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet. 1998;35:331–45.

    Article  PubMed  CAS  Google Scholar 

  54. Tolliver BK, Desantis SM, Brown DG, Prisciandaro JJ, Brady KT. A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2012;14:54–63.

    Article  PubMed  CAS  Google Scholar 

  55. Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311:1889–900.

    Article  PubMed  CAS  Google Scholar 

  56. Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med. 2008;359:715–21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry. 1997;54:1130–5.

    Article  PubMed  CAS  Google Scholar 

  58. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.

    Article  PubMed  Google Scholar 

  59. O'Malley SS, Krishnan-Sarin S, Farren C, O'Connor PG. Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects. J Clin Psychopharmacol. 2000;20:69–76.

    Article  PubMed  CAS  Google Scholar 

  60. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617–25.

    Article  PubMed  CAS  Google Scholar 

  61. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28:1051–9.

    Article  PubMed  CAS  Google Scholar 

  62. Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs. 2012;73(6):991–7.

    Article  PubMed  Google Scholar 

  63. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994;18:1162–7.

    Article  PubMed  CAS  Google Scholar 

  64. Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 2015;12:e1001924.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9:e87366.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Mohanty SR, LaBrecque DR, Mitros FA, Layden TJ. Liver transplantation for disulfiram-induced fulminant hepatic failure. J Clin Gastroenterol. 2004;38:292–5.

    Article  PubMed  Google Scholar 

  67. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf. 1999;20:427–35.

    Article  PubMed  CAS  Google Scholar 

  68. Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol. 1985;17:107–16.

    Article  PubMed  CAS  Google Scholar 

  69. • Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007. Landmark clinic trial uniquely demonstrating safety of a pharmacotherapy for liver disease in patients with cirrhosis.

  70. • Morley KC, Leung S, Baillie A, Haber PS. The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemp Clin Trials. 2013. Clinical trial currently underway will further demonstrate safety and efficacy of baclofen in patients with alcoholic liver disease.

  71. Morley KC, Baillie A, Leung S, Addolorato G, Leggio L, Haber PS. Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol. 2014;49:654–60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Santos C, Olmedo RE. Sedative-hypnotic drug withdrawal syndrome: recognition and treatment. Emerg Med Pract 2017.

  73. Leung NY, Whyte IM, Isbister GK. Baclofen overdose: defining the spectrum of toxicity. Emerg Med Australas. 2006;18:77–82.

    Article  PubMed  Google Scholar 

  74. Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients—the ALPADIR study. Alcohol Alcohol. 2017;52:439–46.

    Article  PubMed  Google Scholar 

  75. Addolorato G, Mirijello A, Leggio L, Ferrulli A, Landolfi R. Management of alcohol dependence in patients with liver disease. CNS Drugs 2013.

  76. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677–85.

    Article  PubMed  CAS  Google Scholar 

  77. Langtry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997.

  78. Edwards S, Kenna GA, Swift RM, Leggio L. Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. Curr Pharm Des 2011.

  79. Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs. 2018;27:113–24.

    Article  PubMed  CAS  Google Scholar 

  80. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661–9.

    Article  PubMed  CAS  Google Scholar 

  81. Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. Ann Pharmacother 2016.

  82. Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77:403–26.

    Article  PubMed  CAS  Google Scholar 

  83. Kilpatrick GJ, Hagan RM, Gale JD. 5-HT3 and 5-HT4 receptors in terminal regions of the mesolimbic system. Behav Brain Res 1996.

  84. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000;284:963–71.

    Article  PubMed  CAS  Google Scholar 

  85. Ait-Daoud N, Johnson BA, Prihoda TJ, Hargita ID. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology. 2001;154:23–7.

    Article  PubMed  CAS  Google Scholar 

  86. Figg WD, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, et al. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J Clin Pharmacol. 1996;36:206–15.

    Article  PubMed  CAS  Google Scholar 

  87. Le AD, Corrigall WA, Harding JW, Juzytsch W, Li TK. Involvement of nicotinic receptors in alcohol self-administration. Alcohol Clin Exp Res. 2000;24:155–63.

    Article  PubMed  CAS  Google Scholar 

  88. • O'Malley SS, Zweben A, Fucito LM, Wu R, Piepmeier ME, Ockert DM et al. Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: a randomized clinical trial. JAMA Psychiatry. 2018. Recent evidence for use of varenicline in patients with co-morbid cigarette smoking which is a very commonly encountered clinical situation.

  89. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006.

  90. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92–9.

    Article  PubMed  CAS  Google Scholar 

  91. Feeney GF, Connor JP, Young RM, Tucker J, McPherson A. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres’ experience with pharmacotherapy. Alcohol Alcohol. 2006;41:321–7.

    Article  PubMed  CAS  Google Scholar 

  92. Kiefer F, Wiedemann K. Combined therapy: what does acamprosate and naltrexone combination tell us? Alcohol Alcohol. 2004;39:542–7.

    Article  PubMed  CAS  Google Scholar 

  93. • Haber PS, Morley KC. The impact of alcohol pharmacotherapies on public health in Australia is limited by low prescribing rates. Public Health Res Pract. 2016. Recent retrospective data demontrating low levels of pharmacothearpy use and short duration of use in Australia.

Download references

Author information

Authors and Affiliations

  1. Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia

    Ted M. Stoklosa, Anastasia Volovets & Paul S. Haber

  2. A.W Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, 2050, Australia

    Ted M. Stoklosa & Anastasia Volovets

  3. NHMRC Centre of Research Excellence in Mental Health and Substance Use, Central Clinical School, Sydney Medical School, University of Sydney, Sydney, NSW, Australia

    Kirsten C. Morley & Paul S. Haber

Authors
  1. Ted M. Stoklosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kirsten C. Morley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anastasia Volovets
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul S. Haber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ted M. Stoklosa.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Alcohol

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stoklosa, T.M., Morley, K.C., Volovets, A. et al. Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease. Curr Addict Rep 5, 287–296 (2018). https://doi.org/10.1007/s40429-018-0211-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40429-018-0211-1

Keywords

Search

Navigation